Kbc Group Nv Exelixis, Inc. Transaction History

Kbc Group Nv

$32.2 Billion
Q1 2025

A detailed history of Kbc Group Nv transactions in Exelixis, Inc. stock. As of the latest transaction made, Kbc Group Nv holds 17,221 shares of EXEL stock, worth $718,976. This represents 0.0% of its overall portfolio holdings.

Number of Shares

17,221

Previous 10,514 63.79%

Holding current value

$718,976

Previous $350,000 81.71%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 25, 2025	BUY	$32.38 - $39.16 $217,172 - $262,646	6,707 Added 63.79%	17,221 $636,000
Q4 2024 Jan 22, 2025	BUY	$25.39 - $36.46 $84,599 - $121,484	3,332 Added 46.39%	10,514 $350,000
Q2 2024 Jul 17, 2024	BUY	$20.34 - $23.73 $23,370 - $27,265	1,149 Added 19.05%	7,182 $161,000
Q4 2023 Feb 13, 2024	BUY	$19.25 - $24.13 $116,135 - $145,576	6,033 New	6,033 $145,000
Q1 2020 May 04, 2020	SELL	$14.46 - $21.8 $133,610 - $201,432	-9,240 Closed	0 $0
Q3 2019 Nov 07, 2019	SELL	$17.68 - $22.65 $413,057 - $529,171	-23,363 Reduced 71.66%	9,240 $163,000
Q2 2019 Jul 30, 2019	BUY	$18.93 - $24.75 $196,928 - $257,474	10,403 Added 46.86%	32,603 $0
Q2 2018 Aug 03, 2018	SELL	$18.56 - $22.45 $5.73 Million - $6.93 Million	-308,666 Reduced 93.29%	22,200 $0
Q1 2018 May 09, 2018	SELL	$22.15 - $31.89 $3.79 Million - $5.45 Million	-171,042 Reduced 34.08%	330,866 $0
Q4 2017 Feb 07, 2018	SELL	$24.23 - $30.93 $3.02 Million - $3.85 Million	-124,612 Reduced 19.89%	501,908 $0
Q3 2017 Nov 13, 2017	BUY	$23.35 - $29.24 $14.6 Million - $18.3 Million	626,520	626,520 $0

Others Institutions Holding EXEL

# of Institutions

613

Shares Held

257M

Call Options Held

1.57M

Put Options Held

730K

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $13.4B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.

Account